Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.
What happened
FDA reviewed the firm's electronic Drug Registration and Listing System (eDRLS) drug listing information and found mismatches between the labeling and listing files. For Mylanta 2go Antacid Double Strength, the label listed aluminum hydroxide, magnesium hydroxide, and simethicone as active ingredients, but the electronic listing file listed aluminum hydroxide and dimethiconol as active and magnesium hydroxide as inactive. For Microlax Enema, the label listed sodium citrate, sodium lauryl sulfoacetate, and sorbitol as active ingredients, but the listing file listed only sorbitol as active and the other two as inactive.
What FDA found
For Mylanta 2go Antacid Double Strength, the electronic listing file did not match the label's active ingredients: it listed aluminum hydroxide and dimethiconol as active and magnesium hydroxide as inactive, while the label listed aluminum hydroxide, magnesium hydroxide, and simethicone as active.
section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(4)For Microlax Enema, the electronic listing file listed only sorbitol as active and sodium lauryl sulfoacetate and sodium citrate as inactive, while the label listed sodium citrate, sodium lauryl sulfoacetate, and sorbitol as active.
section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(4)The firm did not fulfill its drug listing obligations under section 510(j).
section 510(j) of the FD&C Act, 21 U.S.C. 360(j); section 301(p) of the FD&C Act, 21 U.S.C. 331(p)Because the drugs were not properly listed with FDA, they are misbranded.
section 502(o) of the FD&C Act, 21 U.S.C. 352(o)Introducing or delivering these misbranded drugs into interstate commerce is prohibited.
section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA asks the firm to correct the listing deficiencies, including for all other products it distributes, and to notify FDA in writing within 15 working days of the steps taken, related documentation, and steps to prevent recurrence; if it cannot complete corrections in that time, it must state the reason and expected completion time.
Who should pay attention
- brand owners of OTC drugs listed with FDA
- firms managing eDRLS drug listing files
- companies distributing Mylanta or Microlax products
This is a summary. Read the original letter on fda.gov.